s_id
stringlengths 2
9
| r_id
stringlengths 2
6
| e_id
stringlengths 2
10
| s_label
stringlengths 1
250
| r_label
stringlengths 2
66
| e_label
stringlengths 1
265
|
|---|---|---|---|---|---|
Q37127075 | P2860 | Q81405449 | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | cites work | Assessment of job stress dimensions based on the job demands- control model of employees of telecommunication and electric power companies in Japan: reliability and validity of the Japanese version of the Job Content Questionnaire |
Q37127075 | P2860 | Q83567002 | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | cites work | Acute effects of stretching exercise on the heart rate variability in subjects with low flexibility levels |
Q37127075 | P2860 | Q84507432 | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | cites work | Self-assessed health and menopausal symptoms among 50-year-old Japanese women: cross-sectional surveys in Northern Kawasaki in 1998 and 2008 |
Q37127075 | P2860 | Q61965532 | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | cites work | Nonhormonal management of menopause-associated vasomotor symptoms |
Q37127075 | P407 | Q1860 | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | language of work or name | English |
Q37127082 | P31 | Q101352 | Skedel | instance of | family name |
Q37127082 | P282 | Q8229 | Skedel | writing system | Latin script |
Q37127082 | P5323 | Q92953148 | Skedel | attested in | 2010 United States Census surname index |
Q37127097 | P31 | Q13442814 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | instance of | scholarly article |
Q37127097 | P31 | Q7318358 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | instance of | review article |
Q37127097 | P1433 | Q15756323 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | published in | Medical Science Monitor |
Q37127097 | P2860 | Q38818068 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | A Novel Homozygous SLC2A9 Mutation Associated with Renal-Induced Hypouricemia. |
Q37127097 | P2860 | Q38982043 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction |
Q37127097 | P2860 | Q36648828 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Entacapone is an Antioxidant More Potent than Vitamin C and Vitamin E for Scavenging of Hypochlorous Acid and Peroxynitrite, and the Inhibition of Oxidative Stress-Induced Cell Death. |
Q37127097 | P2860 | Q38723885 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | A Case Report of Familial Renal Hypouricemia Confirmed by Genotyping of SLC22A12, and a Literature Review |
Q37127097 | P2860 | Q36506786 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis |
Q37127097 | P2860 | Q26772053 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid in metabolic syndrome: From an innocent bystander to a central player |
Q37127097 | P2860 | Q38603701 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Febuxostat-induced acute liver injury. |
Q37127097 | P2860 | Q36310374 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis |
Q37127097 | P2860 | Q38583375 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis |
Q37127097 | P2860 | Q38574048 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies |
Q37127097 | P2860 | Q38543455 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Global epidemiology of gout: prevalence, incidence and risk factors |
Q37127097 | P2860 | Q38306645 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. |
Q37127097 | P2860 | Q38216608 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme |
Q37127097 | P2860 | Q38215443 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Is it time to revise the normal range of serum uric acid levels? |
Q37127097 | P2860 | Q33913203 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids |
Q37127097 | P2860 | Q34466066 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol initiation and all-cause mortality in the general population |
Q37127097 | P2860 | Q27681817 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Evolutionary history and metabolic insights of ancient mammalian uricases |
Q37127097 | P2860 | Q39033643 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Impact of allopurinol on risk of myocardial infarction |
Q37127097 | P2860 | Q33643436 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. |
Q37127097 | P2860 | Q37277498 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout |
Q37127097 | P2860 | Q38123116 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. |
Q37127097 | P2860 | Q39147539 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells |
Q37127097 | P2860 | Q36712438 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Chronic hyperuricemia, uric acid deposit and cardiovascular risk |
Q37127097 | P2860 | Q38049115 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hyperuricaemia: more than just a cause of gout? |
Q37127097 | P2860 | Q24612292 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia |
Q37127097 | P2860 | Q38043760 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Oral delivery of anticancer drugs III: formulation using drug delivery systems. |
Q37127097 | P2860 | Q37987490 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Regulation of uric acid excretion by the kidney |
Q37127097 | P2860 | Q39673748 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol causing drug rash with eosinophilia and systemic symptoms syndrome: a challenging diagnosis |
Q37127097 | P2860 | Q34812986 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Molybdenum enzymes in higher organisms |
Q37127097 | P2860 | Q27665100 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase |
Q37127097 | P2860 | Q37780849 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Gout therapeutics: new drugs for an old disease |
Q37127097 | P2860 | Q28283310 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Urate-lowering therapy for gout: focus on febuxostat |
Q37127097 | P2860 | Q38377456 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study |
Q37127097 | P2860 | Q28295637 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Protein glycation inhibitors from the fruiting body of Phellinus linteus |
Q37127097 | P2860 | Q27651033 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol |
Q37127097 | P2860 | Q36897032 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | The changing epidemiology of gout |
Q37127097 | P2860 | Q24645400 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Nitric oxide and peroxynitrite in health and disease |
Q37127097 | P2860 | Q34585155 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid |
Q37127097 | P2860 | Q37156498 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid and inflammatory markers |
Q37127097 | P2860 | Q24652967 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol |
Q37127097 | P2860 | Q28253777 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases |
Q37127097 | P2860 | Q29619497 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Molecular identification of a danger signal that alerts the immune system to dying cells |
Q37127097 | P2860 | Q34527595 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid: an important antioxidant in acute ischaemic stroke |
Q37127097 | P2860 | Q34148117 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity |
Q37127097 | P2860 | Q34143544 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Xanthine oxidoreductase and xanthine oxidase in human cornea |
Q37127097 | P2860 | Q24297979 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Molecular identification of a renal urate anion exchanger that regulates blood urate levels |
Q37127097 | P2860 | Q34129222 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system |
Q37127097 | P2860 | Q34059685 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Molecular regulation of adipogenesis |
Q37127097 | P2860 | Q24650500 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion |
Q37127097 | P2860 | Q33553124 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Acute adverse reactions attributed to allopurinol in hospitalised patients |
Q37127097 | P2860 | Q24617394 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis |
Q37127097 | P2860 | Q34234593 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Similar Functions of Uric Acid and Ascorbate in Man ? |
Q37127097 | P2860 | Q33569027 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Factors affecting urate solubility in vitro |
Q37127097 | P2860 | Q34485521 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis |
Q37127097 | P2860 | Q40006291 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. |
Q37127097 | P2860 | Q40166507 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. |
Q37127097 | P2860 | Q40576886 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. |
Q37127097 | P2860 | Q40468030 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. |
Q37127097 | P2860 | Q41118604 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Association between serum uric acid and nonalcoholic fatty liver disease in the US population. |
Q37127097 | P2860 | Q42829265 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress |
Q37127097 | P2860 | Q42477084 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hyperuricemia induces endothelial dysfunction |
Q37127097 | P2860 | Q41769762 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid |
Q37127097 | P2860 | Q50887703 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats. |
Q37127097 | P2860 | Q50236324 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | 9-Benzoyl 9-deazaguanines as potent xanthine oxidase inhibitors. |
Q37127097 | P2860 | Q53420327 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. |
Q37127097 | P2860 | Q51722188 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors. |
Q37127097 | P2860 | Q48040305 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | A brief history of uric acid: From gout to cardiovascular risk factor. |
Q37127097 | P2860 | Q53600813 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors. |
Q37127097 | P2860 | Q41529646 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkylidene-thiazol-4-ones. |
Q37127097 | P2860 | Q53061295 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. |
Q37127097 | P2860 | Q46935245 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Identification of a potent xanthine oxidase inhibitor from oxidation of caffeic acid |
Q37127097 | P2860 | Q44508268 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. |
Q37127097 | P2860 | Q54373597 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors. |
Q37127097 | P2860 | Q43916216 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules |
Q37127097 | P2860 | Q43267657 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Insights into the inhibition of xanthine oxidase by curcumin |
Q37127097 | P2860 | Q46271681 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial |
Q37127097 | P2860 | Q46401872 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study |
Q37127097 | P2860 | Q55044537 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. |
Q37127097 | P2860 | Q46853314 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy |
Q37127097 | P2860 | Q45287056 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study |
Q37127097 | P2860 | Q44693310 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Inhibition by uric acid of free radicals that damage biological molecules |
Q37127097 | P2860 | Q44539175 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus |
Q37127097 | P2860 | Q44095772 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Iron regulates xanthine oxidase activity in the lung |
Q37127097 | P2860 | Q48127676 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Cellular expression of xanthine oxidoreductase protein in normal human tissues. |
Q37127097 | P2860 | Q50892424 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | The epidemiology of hyperuricaemia and gout in Taiwan aborigines. |
Q37127097 | P2860 | Q56965917 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Urate-Lowering Drugs and Prevention of Cardiovascular Disease: The Emerging Role of Xanthine Oxidase Inhibition |
Q37127097 | P2860 | Q57415259 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? |
Q37127097 | P2860 | Q84812393 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | N-(1,3-Diaryl-3-oxopropyl)amides as a new template for xanthine oxidase inhibitors |
Q37127097 | P2860 | Q70796449 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Blood uric acid level and IQ: a study in twin families |
Subsets and Splits